PMID- 40972530
OWN - NLM
STAT- MEDLINE
DCOM- 20250919
LR  - 20250919
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 188
IP  - 19
DP  - 2025 Sep 18
TI  - Multi-adjuvant personalized neoantigen vaccines: Fine-tuning anti-cancer T cells.
PG  - 5121-5123
LID - S0092-8674(25)00980-8 [pii]
LID - 10.1016/j.cell.2025.08.025 [doi]
AB  - Personalized cancer vaccines aim to broaden the anti-tumor T cell repertoire by 
      targeting neoantigens unique to each patient's tumor, but immunogenicity has been 
      inconsistent. In this issue of Cell, Blass, Keskin, Tu et al. evaluate 
      NeoVax(MI), a multi-adjuvant personalized synthetic long-peptide vaccine 
      administered with nivolumab in patients with melanoma. NeoVax(MI) elicited 
      stronger CD4(+) and CD8(+) responses than earlier iterations, and vaccine-induced 
      T cells trafficked to regressing metastatic lesions.
CI  - Copyright Â© 2025 Elsevier Inc. All rights reserved.
FAU - Wang, Hejia Henry
AU  - Wang HH
AD  - Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins 
      University, Baltimore, MD, USA; Johns Hopkins Convergence Institute, Johns 
      Hopkins University School of Medicine, Baltimore, MD, USA.
FAU - Zaidi, Neeha
AU  - Zaidi N
AD  - Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins 
      University, Baltimore, MD, USA; Johns Hopkins Convergence Institute, Johns 
      Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: 
      nzaidi1@jhmi.edu.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
RN  - 0 (Cancer Vaccines)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Adjuvants, Immunologic)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Humans
MH  - *Cancer Vaccines/immunology/therapeutic use
MH  - *Antigens, Neoplasm/immunology
MH  - Precision Medicine
MH  - *Melanoma/immunology/therapy
MH  - *T-Lymphocytes/immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - *Adjuvants, Immunologic
MH  - Nivolumab
MH  - CD4-Positive T-Lymphocytes/immunology
COIS- Declaration of interests N.Z. reports research support from Bristol Myers Squibb, 
      is a consultant for Genentech and Adventris, and receives other support from 
      Adventris Pharmaceuticals.
EDAT- 2025/09/20 00:32
MHDA- 2025/09/20 00:33
CRDT- 2025/09/19 18:17
PHST- 2025/08/11 00:00 [received]
PHST- 2025/08/14 00:00 [revised]
PHST- 2025/08/15 00:00 [accepted]
PHST- 2025/09/20 00:33 [medline]
PHST- 2025/09/20 00:32 [pubmed]
PHST- 2025/09/19 18:17 [entrez]
AID - S0092-8674(25)00980-8 [pii]
AID - 10.1016/j.cell.2025.08.025 [doi]
PST - ppublish
SO  - Cell. 2025 Sep 18;188(19):5121-5123. doi: 10.1016/j.cell.2025.08.025.
